Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy

Published:2020-07-10 Issue:9 Volume:12 Page:
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Zuazo Miren¹,Arasanz Hugo¹²,Bocanegra Ana¹,Chocarro Luisa¹,Vera Ruth²^ORCID,Escors David¹,Kagamu Hiroshi³^ORCID,Kochan Grazyna¹

Affiliation:

1. Navarrabiomed‐UPNA IdISNA Pamplona Spain

2. Complejo Hospitalario de Navarra‐IdISNA Pamplona Spain

3. Saitama Medical University International Medical Center Hidaka Japan

Funder

Instituto de Salud Carlos III

Fundación Científica Asociación Española Contra el Cáncer

Japan Agency for Medical Research and Development

Departamento de Educación, Gobierno de Navarra

Japan Society for the Promotion of Science

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/emmm.202012706

Reference10 articles.

1. Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics

2. CD4+ T cell help in cancer immunology and immunotherapy

3. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

4. CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy

5. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fractalkine in Health and Disease;International Journal of Molecular Sciences;2024-07-23

2. PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets;EMBO Molecular Medicine;2024-07-19

3. Evaluating the immunologically “cold” tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models;Breast Cancer Research;2024-06-25

4. Clinical features and prognostic biomarkers of patients with the rare SMACRA4 gene mutation in non-small cell lung cancer;2023-12-22

5. Plasma fractalkine contributes to systemic myeloid diversity and PD‐L1/PD‐1 blockade in lung cancer;EMBO reports;2023-06-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3